Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

NCT01177813 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

986

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo identical to BI10773 high dose
DRUG: BI 10773
DRUG: BI 10773 open label
DRUG: Placebo identical to BI10773 low dose
DRUG: Placebo identical to BI10773 low dose
DRUG: Placebo identical to BI10773 high dose
DRUG: Placebo identical to Sitagliptin 100mg
DRUG: Placebo identical to Sitagliptin 100mg
DRUG: BI10773
DRUG: Sitagliptin
DRUG: Placebo identical to Sitagliptin 100mg
DRUG: Placebo identical to BI10773 low dose
DRUG: Placebo identical to BI10773 high dose

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]